Extracellular matrix turnover and outflow resistance
- PMID: 19087875
- PMCID: PMC2700052
- DOI: 10.1016/j.exer.2008.11.023
Extracellular matrix turnover and outflow resistance
Abstract
Normal homeostatic adjustment of elevated intraocular pressure (IOP) involves remodeling the extracellular matrix (ECM) of the trabecular meshwork (TM). This entails sensing elevated IOP, releasing numerous activated proteinases to degrade existing ECM and concurrent biosynthesis of replacement ECM components. To increase or decrease IOP, the quantity, physical properties and/or organization of new components should be somewhat different from those replaced in order to modify outflow resistance. ECM degradation and replacement biosynthesis in the outflow pathway must be tightly controlled and focused to retain the complex structural organization of the tissue. Recently identified podosome- or invadopodia-like structures (PILS) may aid in the focal degradation of ECM and organization of replacement components.
Figures
Similar articles
-
Pressure-induced expression changes in segmental flow regions of the human trabecular meshwork.Exp Eye Res. 2017 May;158:67-72. doi: 10.1016/j.exer.2016.06.009. Epub 2016 Jun 19. Exp Eye Res. 2017. PMID: 27334250 Free PMC article. Review.
-
Specialized podosome- or invadopodia-like structures (PILS) for focal trabecular meshwork extracellular matrix turnover.Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5353-65. doi: 10.1167/iovs.07-1666. Epub 2008 Jul 18. Invest Ophthalmol Vis Sci. 2008. PMID: 18641286 Free PMC article.
-
Extracellular matrix in the trabecular meshwork.Exp Eye Res. 2008 Apr;86(4):543-61. doi: 10.1016/j.exer.2008.01.013. Epub 2008 Jan 25. Exp Eye Res. 2008. PMID: 18313051 Free PMC article. Review.
-
Differential effects of caveolin-1 and -2 knockdown on aqueous outflow and altered extracellular matrix turnover in caveolin-silenced trabecular meshwork cells.Invest Ophthalmol Vis Sci. 2014 Aug 7;55(9):5497-509. doi: 10.1167/iovs.14-14519. Invest Ophthalmol Vis Sci. 2014. PMID: 25103269 Free PMC article.
-
Matrix Metalloproteinases and Glaucoma Treatment.J Ocul Pharmacol Ther. 2020 May;36(4):208-228. doi: 10.1089/jop.2019.0146. Epub 2020 Apr 1. J Ocul Pharmacol Ther. 2020. PMID: 32233938 Free PMC article. Review.
Cited by
-
Development of a model of elevated intraocular pressure in rats by gene transfer of bone morphogenetic protein 2.Invest Ophthalmol Vis Sci. 2013 Aug 13;54(8):5441-55. doi: 10.1167/iovs.13-11651. Invest Ophthalmol Vis Sci. 2013. PMID: 23821199 Free PMC article.
-
Contribution of the latent transforming growth factor-β binding protein 2 gene to etiology of primary open angle glaucoma and pseudoexfoliation syndrome.Mol Vis. 2013;19:333-47. Epub 2013 Feb 7. Mol Vis. 2013. PMID: 23401661 Free PMC article.
-
Sustained release of matrix metalloproteinase-3 to trabecular meshwork cells using biodegradable PLGA microparticles.Mol Pharm. 2013 Aug 5;10(8):3023-3032. doi: 10.1021/mp4001052. Epub 2013 Jul 18. Mol Pharm. 2013. PMID: 23795867 Free PMC article.
-
Human trabecular meshwork cell behavior is influenced by collagen scaffold pore architecture and glycosaminoglycan composition.Biotechnol Bioeng. 2020 Oct;117(10):3150-3159. doi: 10.1002/bit.27477. Epub 2020 Jul 9. Biotechnol Bioeng. 2020. PMID: 32589791 Free PMC article.
-
Toll-Like Receptor 4 Signaling in the Trabecular Meshwork.Front Cell Dev Biol. 2022 Jul 15;10:936115. doi: 10.3389/fcell.2022.936115. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35912101 Free PMC article. Review.
References
-
- Alexander JP, Samples JR, et al. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276–285. - PubMed
-
- Alexander JP, Samples JR, et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172–180. - PubMed
-
- Ando H, Twining SS, et al. MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541–3548. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- EY010572/EY/NEI NIH HHS/United States
- EY003279/EY/NEI NIH HHS/United States
- P30 EY010572/EY/NEI NIH HHS/United States
- R01 EY003279/EY/NEI NIH HHS/United States
- EY008247/EY/NEI NIH HHS/United States
- P30 EY010572-149002/EY/NEI NIH HHS/United States
- R01 EY008247/EY/NEI NIH HHS/United States
- R01 EY008247-19A1/EY/NEI NIH HHS/United States
- R01 EY003279-28/EY/NEI NIH HHS/United States
- R01 EY008247-18/EY/NEI NIH HHS/United States
- P30 EY010572-139002/EY/NEI NIH HHS/United States
- R01 EY003279-27/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources